Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives

References

• HillestadLKAcute promyelocytic leukemiaActa Med Scand1957159318919413508085
   PubMedGoogle Scholar
• PisciottaAVSchulzEJFibrinolytic purpura in acute leukemiaAm J Med195519582482813268484
   PubMedGoogle Scholar
• CooperbergAANeimanGMAFibrinogenopenia and fibrinolysis in acute myelogenous leukemiaAnn Intern Med195542370671114350491
   PubMedGoogle Scholar
• CroizatPFavre-GillyJLes aspects du syndrome hémorragique des leucémies; à propos de 12 cas de thrombocytopénie et d’un cas de fibrinopénie [Aspects of the leukemia hemorrhagic syndrome; in 12 cases of thrombocytopenia and one case of fibrinopenia]Sang1949207417421 French15403133
   PubMedGoogle Scholar
• RizakEDie Fibrinopenie [The Fibrinopenia]Z Klin Med1935128605 German
   Google Scholar
• BernardJMatheGBoulayJCeoardBChomeJLa leucemie aiguë à promyelocytes. Étude portant sur vingt observations [Acute promyelocytic leukemia: a study made on 20 cases]Schweiz Med Wochenschr195989604608 French13799642
   PubMedGoogle Scholar
• GrimwadeDHillsRKMoormanAVNational Cancer Research Institute Adult Leukaemia Working GroupRefinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trialsBlood2010116335436520385793
   PubMed Web of Science ®Google Scholar
• LehmannSRavnACarlssonLContinuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia RegistryLeukemia20112571128113421502956
   PubMed Web of Science ®Google Scholar
• RegoEMJácomoRHEpidemiology and treatment of acute promyelocytic leukemia in Latin AmericaMediterr J Hematol Infect Dis201131e201104922110899
   PubMedGoogle Scholar
• DouerDThe epidemiology of acute promyelocytic leukaemiaBest Prac Res Clin Haematol2003163357367
   PubMed Web of Science ®Google Scholar
• BennettJMCatovskyDDanielM-TProposals for the classification of the acute leukaemias French-American-British (FAB) Co-operative GroupBr J Haematol1976334451458188440
   PubMed Web of Science ®Google Scholar
• BennettJMCatovskyDDanielMTA variant form of hypergranular promyelocytic leukaemia (M3)Br J Haematol19804411691706929699
   PubMedGoogle Scholar
• RowleyJDGolombHMDoughertyC15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemiaLancet197718010549550
   PubMed Web of Science ®Google Scholar
• TestaJGolombHRowleyJVardimanJSweetDJHypergranular promyelocytic leukemia (APL): cytogenetic and ultrastructural specificityBlood1978522272280276386
   PubMedGoogle Scholar
• SwerdlowSHCEHarrisLJaffeESWHO Classification of Tumours of Haematopoietic and Lymphoid TissueLyonThe International Agency for Research on Cancer2008
   Google Scholar
• ArberDAOraziAHasserjianRThe 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemiaBlood2016127202391240527069254
   PubMed Web of Science ®Google Scholar
• MadanVShyamsunderPHanLComprehensive mutational analysis of primary and relapse acute promyelocytic leukemiaLeukemia2016301672168127063598
   PubMed Web of Science ®Google Scholar
• NCI (NIH) [webpage on the Internet]SEER Stat Fact Sheets: Acute Myeloid Leukemia (AML)NIH (online)2016 Available from: http://seer.cancer.gov/statfacts/html/amyl.htmlAccessed November 3, 2016
   Google Scholar
• AppelbaumFRGundackerHHeadDRAge and acute myeloid leukemiaBlood200610793481348516455952
   PubMed Web of Science ®Google Scholar
• PulteDGondosABrennerHImprovements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st centuryHaematologica200893459460018322250
   PubMed Web of Science ®Google Scholar
• DöhnerHWeisdorfDJBloomfieldCDAcute myeloid leukemiaN Engl J Med20153731136115226376137
   PubMed Web of Science ®Google Scholar
• GrimwadeDWalkerHOliverFThe importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trialBlood199892232223339746770
   PubMed Web of Science ®Google Scholar
• SlovakMLKopeckyKJCassilethPAKaryotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group studyBlood200096134075408311110676
   PubMed Web of Science ®Google Scholar
• ByrdJCMrozekKDodgeRKCancer and Leukemia Group B (CALGB 8461)Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood2002100134325433612393746
   PubMed Web of Science ®Google Scholar
• SchnittgerSSchochCKernWNucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotypeBlood2005106123733373916076867
   PubMed Web of Science ®Google Scholar
• ThiedeCKochSCreutzigEPrevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)Blood2006107104011402016455956
   PubMed Web of Science ®Google Scholar
• MrózekKMarcucciGPaschkaPWhitmanSPBloomfieldCDClinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Blood2007109243144816960150
   PubMed Web of Science ®Google Scholar
• SchlenkRFDöhnerKKrauterJGerman-Austrian Acute Myeloid Leukemia Study GroupMutations and treatment outcome in cytogenetically normal acute myeloid leukemiaN Engl J Med2008358181909191818450602
   PubMed Web of Science ®Google Scholar
• HouHALinLIChenCYTienHFReply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis’Br J Cancer2009101473874019623175
   PubMed Web of Science ®Google Scholar
• PabstTEyholzerMFosJMuellerBUHeterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosisBr J Cancer200910081343134619277035
   PubMed Web of Science ®Google Scholar
• WoutersBJLöwenbergBErpelinck-VerschuerenCAJvan PuttenWLJValkPJMDelwelRDouble CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcomeBlood20091133088309119171880
   PubMed Web of Science ®Google Scholar
• DufourASchneiderFMetzelerKHAcute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcomeJ Clin Oncol201028457057720038735
   PubMed Web of Science ®Google Scholar
• GreenCLKooKKHillsRKBurnettAKLinchDCGaleREPrognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutationsJ Clin Oncol201028162739274720439648
   PubMed Web of Science ®Google Scholar
• TaskesenEBullingerLCorbaciogluAPrognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entityBlood201111782469247521177436
   PubMed Web of Science ®Google Scholar
• EsteyEGarcia-ManeroGFerrajoliAUse of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemiaBlood200610793469347316373661
   PubMed Web of Science ®Google Scholar
• PowellBLMoserBStockWArsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Blood2010116193751375720705755
   PubMed Web of Science ®Google Scholar
• SanzMAMontesinosPRayonCPETHEMA and HOVON GroupsRisk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcomeBlood2010115255137514620393132
   PubMed Web of Science ®Google Scholar
• IlandHJBradstockKSuppleSGAustralasian Leukaemia and Lymphoma GroupAll-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Blood201212081570158022715121
   PubMed Web of Science ®Google Scholar
• Lo-CocoFAvvisatiGVignettiMGruppo Italiano Malattie Ematologiche dell’Adulto, the German–Austrian Acute Myeloid Leukemia Study Group, and Study Alliance LeukemiaRetinoic acid and arsenic trioxide for acute promyelocytic leukemiaN Engl J Med2013369211112123841729
   PubMed Web of Science ®Google Scholar
• BurnettAKRussellNHHillsRKthe UK National Cancer Research Institute Acute Myeloid Leukaemia Working GroupArsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trialLancet Oncol201516131295130526384238
   PubMed Web of Science ®Google Scholar
• IlandHJCollinsMBradstockKAustralasian Leukaemia and Lymphoma GroupUse of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialLancet Haematol201529e357e36626685769
   PubMed Web of Science ®Google Scholar
• Lo-CocoFDi DonatoLSchlenkRFTargeted therapy alone for acute promyelocytic leukemiaN Engl J Med2016374121197119827007970
   PubMed Web of Science ®Google Scholar
• DrapkinRLGeeTSDowlingMDProphylactic heparin therapy in acute promyelocytic leukemiaCancer197841624842490274995
   PubMedGoogle Scholar
• DidisheimPTromboldJSVandervoortRLEMibashanRSAcute promyelocytic leukemia with fibrinogen and factor V deficienciesBlood196423671772814161406
   PubMedGoogle Scholar
• RosenthalRLAcute promyelocytic leukemia associated with hypofibrinogenemiaBlood196321449550813974993
   PubMedGoogle Scholar
• BernardJWeilMBoironMJacquillatCFlandrinGGemonM-FAcute promyelocytic leukemia: results of treatment by daunorubicinBlood19734144894964510926
   PubMed Web of Science ®Google Scholar
• CollinsAJBloomfieldCDPetersonBAMcKennaRWEdsonJAcute promyelocytic leukemia: management of the coagulopathy during daunorubicin-prednisone remission inductionArch Intern Med19781381116771680281191
   PubMedGoogle Scholar
• MartyMGanemGFischerJLeucemie aigue promyelocytaire; etude retrospective de 119 malades traits par Daunorubicine [Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin]Nouv Rev Fr Hematol1984266371378 French6597407
   PubMedGoogle Scholar
• CordonnierCVernantJPBrunBAcute promyelocytic leukemia in 57 previously untreated patientsCancer198555118253855265
   PubMed Web of Science ®Google Scholar
• PettiMCAvvisatiGAmadoriSAcute promyelocytic leukemia: clinical aspects and results of treatment in 62 patientsHaematologica19877221511553114070
   PubMedGoogle Scholar
• SanzMAJarqueIMartínGAcute promyelocytic leukemia. Therapy results and prognostic factorsCancer19886117133422032
   PubMed Web of Science ®Google Scholar
• CunninghamIGeeTReichLKempinSNavalAClarksonBAcute promyelocytic leukemia: treatment results during a decade at Memorial HospitalBlood1989735111611222930837
   PubMed Web of Science ®Google Scholar
• AvvisatiGMandelliFPettiMCIdarubicin (4-demethoxydauno-rubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMAEur J Haematol19904442572602188854
   PubMed Web of Science ®Google Scholar
• FenauxPTertianGCastaigneSA randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemiaJ Clin Oncol199199155615611805818
   PubMedGoogle Scholar
• FenauxPPolletJPVandenbossche-SimonLTreatment of acute promyelocytic leukemia: a report of 70 casesLeuk Lymphoma19914423924827463043
   PubMed Web of Science ®Google Scholar
• KantarjianHMKeatingMJWaltersRSAcute promyelocytic leukemiaAm J Med19868057897973458366
   PubMed Web of Science ®Google Scholar
• HeadDKopeckyKJWeickJEffect of aggressive daunomycin therapy on survival in acute promyelocytic leukemiaBlood1995865171717287655004
   PubMed Web of Science ®Google Scholar
• AvvisatiGPettiMCLo-CocoFGIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto) Italian Cooperative GroupInduction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-upBlood200210093141314612384411
   PubMed Web of Science ®Google Scholar
• BreitmanTRSelonickSECollinsSJInduction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acidProc Natl Acad Sci U S A1980775293629406930676
   PubMed Web of Science ®Google Scholar
• BreitmanTRCollinsSJKeeneBRTerminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acidBlood1981576100010046939451
   PubMed Web of Science ®Google Scholar
• ChomienneCBalleriniPBalitrandNAll-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationshipBlood1990769171017172224120
   PubMed Web of Science ®Google Scholar
• WangZ-YChenZAcute promyelocytic leukemia: from highly fatal to highly curableBlood200811152505251518299451
   PubMed Web of Science ®Google Scholar
• RaelsonJNerviCRosenauerAThe PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cellsBlood1996888282628328874178
   PubMedGoogle Scholar
• YoshidaHKitamuraKTanakaKAccelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathwayCancer Res19965613294529488674046
   PubMedGoogle Scholar
• NerviCFerraraFFFanelliMCaspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion proteinBlood1998927224422519746761
   PubMed Web of Science ®Google Scholar
• ZhuJGianniMKopfERetinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteinsProc Natl Acad Sci U S A19999626148071481210611294
   PubMed Web of Science ®Google Scholar
• NasrRGuilleminMCFerhiOEradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradationNat Med200814121333134219029980
   PubMedGoogle Scholar
• LaneAALeyTJNeutrophil elastase cleaves PML-RARalpha and is important for the development of acute promyelocytic leukemia in miceCell2003115330531814636558
   PubMedGoogle Scholar
• HuangMYeYChenSUse of all-trans retinoic acid in the treatment of acute promyelocytic leukemiaBlood19887225675723165295
   PubMed Web of Science ®Google Scholar
• DegosLChomienneCDanielMTTreatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acidLancet1990336872814401441
   PubMed Web of Science ®Google Scholar
• CastaigneSChomienneCDanielMTAll-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical resultsBlood1990769170417092224119
   PubMed Web of Science ®Google Scholar
• WarrellRPJrMaslakPEardleyAHellerGMillerWHJrFrankelSRTreatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experienceLeukemia1994869299338207986
   PubMedGoogle Scholar
• ChenZXXueYQZhangRA clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patientsBlood1991786141314191884013
   PubMed Web of Science ®Google Scholar
• FrankelSREardleyALauwersGWeissMWarrellRPJrThe “retinoic acid syndrome” in acute promyelocytic leukemiaAnn Intern Med199211742922961637024
   PubMed Web of Science ®Google Scholar
• De BottonSDombretHSanzMIncidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL GroupBlood1998928271227189763554
   PubMed Web of Science ®Google Scholar
• LuesinkMPenningsJLAWissinkWMChemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndromeBlood2009114275512552119828696
   PubMed Web of Science ®Google Scholar
• SanzMAMontesinosPHow we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemiaBlood2014123182777278224627526
   PubMed Web of Science ®Google Scholar
• SanzMAGrimwadeDTallmanMSManagement of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood200911391875189118812465
   PubMed Web of Science ®Google Scholar
• WileyJSFirkinFCReduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study GroupLeukemia1995957747787769839
   PubMed Web of Science ®Google Scholar
• KelaidiCChevretSDe BottonSImproved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: The European APL Group ExperienceJ Clin Oncol200927162668267619414681
   PubMed Web of Science ®Google Scholar
• MontesinosPBerguaJMVellengaEDifferentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factorsBlood2009113477578318945964
   PubMed Web of Science ®Google Scholar
• FenauxPChevretSGuerciALong-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL groupLeukemia20001481371137710942231
   PubMed Web of Science ®Google Scholar
• FenauxPLe DeleyMCCastaigneSEffect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 GroupBlood19938211324132498241496
   PubMedGoogle Scholar
• FenauxPChastangCChevretSA randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemiaBlood19999441192120010438706
   PubMed Web of Science ®Google Scholar
• SanzMAMartıńGRayónCA modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemiaBlood19999493015302110556184
   PubMed Web of Science ®Google Scholar
• BurnettAKGrimwadeDSolomonEWheatleyKGoldstoneAHPresenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trialBlood199993124131414310361110
   PubMed Web of Science ®Google Scholar
• AsouNAdachiKTamuraJAnalysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study GroupJ Clin Oncol199816178859440726
   PubMedGoogle Scholar
• TallmanMSAndersenJWSchifferCAAll-trans-retinoic acid in acute promyelocytic leukemia. [Erratum appears in N Engl J Med. 1997;337(22):1639]N Engl J Med199733715102110289321529
   PubMed Web of Science ®Google Scholar
• MandelliFDiverioDAvvisatiGMolecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapyBlood1997903101410219242531
   PubMed Web of Science ®Google Scholar
• AvvisatiGLo CocoFDiverioDAIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot studyBlood1996884139013988695858
   PubMed Web of Science ®Google Scholar
• IlandHBradstockKSeymourJAustralasian Leukaemia and Lymphoma GroupResults of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemiaHaematologica201297222723421993673
   PubMed Web of Science ®Google Scholar
• SanzMACocoFLMartínGDefinition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groupsBlood20009641247125310942364
   PubMed Web of Science ®Google Scholar
• Lo-CocoFAvvisatiGVignettiMItalian GIMEMA Cooperative GroupFront-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA GroupBlood2010116173171317920644121
   PubMed Web of Science ®Google Scholar
• SanzMAMartinGGonzalezMRisk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA groupBlood200410341237124314576047
   PubMed Web of Science ®Google Scholar
• AdèsLChevretSRaffouxEEuropean APL GroupLong-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patientsAm J Hematol201388755655923564205
   PubMedGoogle Scholar
• AdesLSanzMAChevretSTreatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA resultsBlood200811131078108417975017
   PubMedGoogle Scholar
• SanzMAMartinGLo CocoFChoice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemiaBest Prac Clin Haematol2003163433451
   PubMedGoogle Scholar
• BurnettAKHillsRKGrimwadeDUnited Kingdom National Cancer Research Institute Acute Myeloid Leukaemia SubgroupInclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trialLeukemia201327484385123222369
   PubMed Web of Science ®Google Scholar
• MontesinosPGonzalezJDGonzalezJTherapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapyJ Clin Oncol201028243872387920625122
   PubMed Web of Science ®Google Scholar
• BatziosCHayesLAHeSZSecondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia. [Erratum appears in Am J Hematol. 2010;85(7):550]Am J Hematol2009841171571919806661
   PubMedGoogle Scholar
• LobeIRigal-HuguetFVekhoffAEuropean APL Group ExperienceMyelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experienceLeukemia20031781600160412886249
   PubMedGoogle Scholar
• ZompiSViguieFTherapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemiaLeuk Lymphoma200243227528011999558
   PubMed Web of Science ®Google Scholar
• LatagliataRPettiMCFenuSTherapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problemBlood200299382282411806982
   PubMedGoogle Scholar
• Garcia-ManeroGKantarjianHKornblauSEsteyETherapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL)Leukemia20021691888
   PubMedGoogle Scholar
• AndersenMKPedersen-BjergaardJTherapy-related MDS and AML in acute promyelocytic leukemiaBlood20021001928193012211197
   PubMed Web of Science ®Google Scholar
• PellicoriPCalicchiaALococoFCiminoGTorromeoCSubclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocolCongest Heart Fail201218421722122809260
   PubMedGoogle Scholar
• ThomasXLeQHFiereDAnthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemiaAnn Hematol200281950450712373350
   PubMedGoogle Scholar
• AvvisatiGNewly diagnosed acute promyelocytic leukemiaMediterr J Hematol Infect Dis201131e201106422220261
   PubMedGoogle Scholar
• ByrnsMCPenningTMChapter 67 Environmental toxicology: carcinogens and heavy metalsBruntonLLChabnerBAKnollmannBCGoodman and Gilman’s The Pharmacological Basis of Therapeutics, 12eNew York, NYThe McGraw-Hill Companies2011
   Google Scholar
• ChenSJZhouGBZhangXWMaoJHde TheHChenZFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaBlood2011117246425643721422471
   PubMed Web of Science ®Google Scholar
• ForknerCEScottTArsenic as a therapeutic agent in chronic myelogenous leukemia: preliminary reportJ Am Med Assoc193197135
   Google Scholar
• KwongYLToddDDelicious poison: arsenic trioxide for the treatment of leukemiaBlood1997899348734879129058
   PubMedGoogle Scholar
• ShenZXChenGQNiJHUse of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patientsBlood1997899335433609129042
   PubMed Web of Science ®Google Scholar
• ChenGQShiXGTangWUse of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cellsBlood1997899334533539129041
   PubMed Web of Science ®Google Scholar
• de TheHLe BrasMLallemand-BreitenbachVThe cell biology of disease: acute promyelocytic leukemia, arsenic, and PML bodiesJ Cell Biol20121981112122778276
   PubMed Web of Science ®Google Scholar
• JeanneMLallemand-BreitenbachVFerhiOPML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3Cancer Cell2010181889820609355
   PubMed Web of Science ®Google Scholar
• ZhangX-WYanX-JZhouZ-RArsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.[Erratum appears in Science. 2010;328(5981):974]Science2010328597524024320378816
   PubMed Web of Science ®Google Scholar
• Lallemand-BreitenbachVJeanneMBenhendaSArsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathwayNat Cell Biol200810554755518408733
   PubMed Web of Science ®Google Scholar
• TathamMHGeoffroyM-CShenLRNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradationNat Cell Biol200810553854618408734
   PubMed Web of Science ®Google Scholar
• dos SantosGAKatsLPandolfiPPSynergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemiaJ Exp Med2013210132793280224344243
   PubMed Web of Science ®Google Scholar
• Lallemand-BreitenbachVGuilleminMCJaninARetinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemiaJ Exp Med199918971043105210190895
   PubMed Web of Science ®Google Scholar
• RegoEMHeLZWarrellRPJrWangZGPandolfiPPRetinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteinsProc Natl Acad Sci U S A20009718101731017810954752
   PubMed Web of Science ®Google Scholar
• SoignetSLFrankelSRDouerDUnited States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemiaJ Clin Oncol200119183852386011559723
   PubMed Web of Science ®Google Scholar
• SoignetSLMaslakPWangZGComplete remission after treatment of acute promyelocytic leukemia with arsenic trioxideN Engl J Med199833919134113489801394
   PubMed Web of Science ®Google Scholar
• AuWYLieAKWChimCSArsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemiaAnn Oncol200314575275712702530
   PubMedGoogle Scholar
• LazoGKantarjianHEsteyEThomasDO’BrienSCortesJUse of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experienceCancer20039792218222412712474
   PubMedGoogle Scholar
• NiuCYanHYuTStudies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patientsBlood199994103315332410552940
   PubMed Web of Science ®Google Scholar
• RaffouxERousselotPPouponJCombined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemiaJ Clin Oncol200321122326233412805334
   PubMed Web of Science ®Google Scholar
• ShigenoKNaitoKSaharaNArsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapiesInt J Hematol200582322422916207595
   PubMedGoogle Scholar
• ThomasXPigneuxARaffouxEHuguetFCaillotDFenauxPSuperiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemiaHaematologica200691799699716757416
   PubMed Web of Science ®Google Scholar
• ShenZ-XShiZ-ZFangJAll-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemiaProc Natl Acad Sci U S A2004101155328533515044693
   PubMed Web of Science ®Google Scholar
• HuJLiuY-FWuC-FLong-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemiaProc Natl Acad Sci U S A200910693342334719225113
   PubMed Web of Science ®Google Scholar
• DaiC-WZhangG-SShenJ-KUse of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. [Erratum appears in Acta Haematol. 2009;121(4):243]Acta Haematol200912111819246888
   PubMedGoogle Scholar
• MathewsVGeorgeBLakshmiKMSingle-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicityBlood200610772627263216352810
   PubMed Web of Science ®Google Scholar
• GhavamzadehAAlimoghaddamKGhaffariSHTreatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapyAnn Oncol200617113113416227315
   PubMed Web of Science ®Google Scholar
• GhavamzadehAAlimoghaddamKRostamiSPhase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemiaJ Clin Oncol201129202753275721646615
   PubMed Web of Science ®Google Scholar
• MathewsVGeorgeBChendamaraiESingle-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up dataJ Clin Oncol201028243866387120644086
   PubMed Web of Science ®Google Scholar
• LeungJPangAYuenW-HKwongY-LTseEWCRelationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cellsBlood2007109274074616968895
   PubMedGoogle Scholar
• RavandiFEsteyEJonesDEffective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicinJ Clin Oncol200927450451019075265
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network [homepage on the Internet]Clinical Practice Guidelines in Oncology2016 Available from: http://www.nccn.org/Accessed January 27, 2017
   Google Scholar
• SeftelMDBarnettMJCoubanSA Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adultsCurr Oncol201421523425025302032
   PubMed Web of Science ®Google Scholar
• PlatzbeckerUAvvisatiGCicconiLImproved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non–high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trialJ Clin Oncol201735660561227400939
   PubMed Web of Science ®Google Scholar
• IlandHJSeymourJFRole of arsenic trioxide in acute promyelocytic leukemiaCurr Treat Options Oncol201314217018423322117
   PubMedGoogle Scholar
• EghtedarARodriguezIKantarjianHIncidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxideLeuk Lymphoma20155651342134525120050
   PubMed Web of Science ®Google Scholar
• ZhuHHuJChenLThe 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemiaBlood20161281525152827402972
   PubMed Web of Science ®Google Scholar
• FirkinFOral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre studyIntern Med J201242894895222906029
   PubMed Web of Science ®Google Scholar
• AuW-YKumanaCRLeeHKKOral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up studyBlood2011118256535654321998212
   PubMed Web of Science ®Google Scholar
• SiuC-WAuW-YYungCEffects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safetyBlood2006108110310616514059
   PubMed Web of Science ®Google Scholar
• AuWYLiC-KLeeVOral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patientsPediatr Blood Cancer201258463063221898784
   PubMed Web of Science ®Google Scholar
• ZhuH-HWuD-PJinJOral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trialJ Clin Oncol201331334215422124127444
   PubMed Web of Science ®Google Scholar
• ZhuH-HWuD-PJinJLong-term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acidBr J Haematol2016174582082227545413
   PubMedGoogle Scholar
• WangLZhouG-BLiuPDissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemiaProc Natl Acad Sci U S A2008105124826483118344322
   PubMed Web of Science ®Google Scholar
• AvvisatiGLo-CocoFPaoloniFPGIMEMA, AIEOP, and EORTC Cooperative GroupsAIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenanceBlood2011117184716472521385856
   PubMed Web of Science ®Google Scholar
• AdesLGuerciARaffouxEEuropean APL GroupVery long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experienceBlood201011591690169620018913
   PubMed Web of Science ®Google Scholar
• AsouNKishimotoYKiyoiHJapan Adult Leukemia Study GroupA randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 studyBlood20071101596617374742
   PubMed Web of Science ®Google Scholar
• TallmanMSAndersenJWSchifferCAAll-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolBlood2002100134298430212393590
   PubMed Web of Science ®Google Scholar
• MuchtarEVidalLRamRGafter-GviliAShpilbergORaananiPThe role of maintenance therapy in acute promyelocytic leukemia in the first complete remissionCochrane Database Syst Rev20133CD00959423543579
   PubMedGoogle Scholar
• GaleREHillsRPizzeyARNCRI Adult Leukaemia Working PartyRelationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemiaBlood2005106123768377616105978
   PubMedGoogle Scholar
• BeitinjanehAJangSRoukozHMajhailNSPrognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic reviewLeuk Res201034783183620096459
   PubMed Web of Science ®Google Scholar
• BarraganEMontesinosPCamosMPETHEMA; HOVON GroupsPrognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapyHaematologica201196101470147721685470
   PubMedGoogle Scholar
• SchnittgerSBacherUHaferlachCKernWAlpermannTHaferlachTClinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARAHaematologica201196121799180721859732
   PubMedGoogle Scholar
• KutnyMAMoserBKLaumannKFLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children’s Oncology GroupPediatr Blood Cancer201259466266722378655
   PubMed Web of Science ®Google Scholar
• CicconiLDivonaMCiardiCPML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukemia treated with ATRA and ATO or ATRA and chemotherapyLeukemia2016301987199227133819
   PubMed Web of Science ®Google Scholar
• TestaULo-CocoFPrognostic factors in acute promyelocytic leukemia: strategies to define high-risk patientsAnn Hematol201695567368026920716
   PubMed Web of Science ®Google Scholar
• LengfelderEHanfsteinBHaferlachCGerman Acute Myeloid Leukemia Cooperative Group (AMLCG)Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative GroupAnn Hematol2013921415223090499
   PubMed Web of Science ®Google Scholar
• LengfelderEHaferlachCSausseleSGerman AML Cooperative GroupHigh dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCGLeukemia200923122248225819741727
   PubMedGoogle Scholar
• McClellanJSKohrtHECoutreSTreatment advances have not improved the early death rate in acute promyelocytic leukemiaHaematologica201297113313621993679
   PubMed Web of Science ®Google Scholar
• MicolJBRaffouxEBoisselNManagement and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trialsEur J Cancer20145061159116824440088
   PubMedGoogle Scholar
• ParkJHQiaoBPanageasKSEarly death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acidBlood201111851248125421653939
   PubMed Web of Science ®Google Scholar
• YanadaMMatsushitaTAsouNSevere hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcomeEur J Haematol200778321321917241371
   PubMed Web of Science ®Google Scholar
• de la SernaJMontesinosPVellengaECauses and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicinBlood200811173395340218195095
   PubMed Web of Science ®Google Scholar
• BreenKAGrimwadeDHuntBJThe pathogenesis and management of the coagulopathy of acute promyelocytic leukaemiaBr J Haematol20121561243622050876
   PubMed Web of Science ®Google Scholar
• KwaanHCCullEHThe coagulopathy in acute promyelocytic leukaemia – what have we learned in the past twenty yearsBest Pract Res Clin Haematol2014271111824907013
   PubMedGoogle Scholar
• MenellJSCesarmanGMJacovinaATMcLaughlinMALevEAHajjarKAAnnexin II and bleeding in acute promyelocytic leukemiaN Engl J Med199934013994100410099141
   PubMed Web of Science ®Google Scholar
• IkezoeTTakeuchiAIsakaMRecombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulationLeuk Res201236111398140222917769
   PubMedGoogle Scholar
• KawanoNKuriyamaTYoshidaSClinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institutionIntern Med2013521556223291674
   PubMedGoogle Scholar
• SaitoAOkamotoYSekiYDIC complicating APL successfully treated with recombinant thrombomodulin alfaJ Pediatr Hematol Oncol2016386e189e19027123666
   PubMedGoogle Scholar
• MeijersJCOudijkEJMosnierLOReduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemiaBr J Haematol2000108351852310759708
   PubMed Web of Science ®Google Scholar
• RegoEMKimHTRuiz-ArguellesGJImproving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APLBlood2013121111935194323319575
   PubMed Web of Science ®Google Scholar
• TestiAMD’AngioMLocatelliFPessionALo CocoFAcute promyelocytic leukemia (APL): comparison between children and adultsMediterr J Hematol Infect Dis201461e201403224804005
   PubMedGoogle Scholar
• BallyCFadlallahJLevergerGOutcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL GroupJ Clin Oncol201230141641164622473162
   PubMedGoogle Scholar
• de BottonSCoiteuxVChevretSOutcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapyJ Clin Oncol20042281404141215084614
   PubMedGoogle Scholar
• MannGReinhardtDRitterJTreatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in childrenAnn Hematol200180741742211529468
   PubMedGoogle Scholar
• OrtegaJJMaderoLMartinGGerman AML Cooperative GroupTreatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA GroupJ Clin Oncol200523307632764016234524
   PubMed Web of Science ®Google Scholar
• TestiAMBiondiALo CocoFGIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in childrenBlood2005106244745315677559
   PubMed Web of Science ®Google Scholar
• CastaigneSLefebvrePChomienneCEffectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemiaBlood19938212356035638260694
   PubMed Web of Science ®Google Scholar
• CreutzigUvan den Heuvel-EibrinkMMGibsonBAML Committee of the International BFM Study GroupDiagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panelBlood2012120163187320522879540
   PubMed Web of Science ®Google Scholar
• CreutzigUZimmermannMDworzakMFavourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline dosesBr J Haematol2010149339940920230404
   PubMedGoogle Scholar
• ImaizumiMTawaAHanadaRProspective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative studyBr J Haematol20111521899820735397
   PubMedGoogle Scholar
• GeorgeBMathewsVPoonkuzhaliBShajiRVSrivastavaAChandyMTreatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experienceLeukemia200418101587159015356649
   PubMed Web of Science ®Google Scholar
• ZhouJZhangYLiJSingle-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemiaBlood201011591697170220029047
   PubMed Web of Science ®Google Scholar
• ChengYZhangLWuJLuAWangBLiuGLong-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experienceEur J Haematol201391648348924033687
   PubMed Web of Science ®Google Scholar
• MilojkovicDApperleyJFHow I treat leukemia during pregnancyBlood2014123797498424269956
   PubMed Web of Science ®Google Scholar
• CulliganDJMerrimanLKellJThe management of acute promyelocytic leukemia presenting during pregnancyClin Leuk200713183191
   Google Scholar
• NaujokasMFAndersonBAhsanHThe broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problemEnviron Health Perspect2013121329530223458756
   PubMed Web of Science ®Google Scholar
• WarrellRPJrFrankelSRMillerWHJrDifferentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)N Engl J Med199132420138513931850498
   PubMed Web of Science ®Google Scholar
• SiuBLAlonzoMRVargoTAFenrichALTransient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancyInt J Gynecol Cancer200212439940212144690
   PubMedGoogle Scholar
• TeradaYShindoTEndohAWatanabeMFukayaTYajimaAFetal arrhythmia during treatment of pregnancy-associated acute promyelocytic leukemia with all-trans retinoic acid and favorable outcomeLeukemia1997113454455
   PubMed Web of Science ®Google Scholar